Fingerprint
Dive into the research topics of 'A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer
R. Tuli, S. L. Shiao, N. Nissen, M. Tighiouart, S. Kim, A. Osipov, M. Bryant, L. Ristow, V. R. Placencio-Hickok, D. Hoffman, S. Rokhsar, K. Scher, S. J. Klempner, P. Noe, M. J. Davis, A. Wachsman, S. Lo, L. Jamil, H. Sandler, S. Piantadosi
Research output: Contribution to journal › Article › peer-review
31
Scopus
citations